Novo Nordisk CEO, On Lilly's Diabetes Drug Approval In China, Says "It's One More Market Where There Will Be Two Critical Contenders Competing"; "Supplying All We Can", There Is No Drug Shortage Of Our Type 2 Diabetes Drug Ozempic In The U.S. Market;...
Novo Nordisk CEO, On Lilly's Diabetes Drug Approval In China, Says "It's One More Market Where There Will Be Two Critical Contenders Competing"; "Supplying All We Can", There Is No Drug Shortage Of Our Type 2 Diabetes Drug Ozempic In The U.S. Market;...
诺和诺德首席执行官在谈到礼来在中国的糖尿病药物批准时说：“这是一个又一个市场，两个关键竞争者将相互竞争”；“尽我们所能供应”，我们的2型糖尿病药物Ozempic在美国市场不存在药物短缺的情况；...
Novo Nordisk CEO, On Lilly's Diabetes Drug Approval In China, Says "It's One More Market Where There Will Be Two Critical Contenders Competing"; "Supplying All We Can", There Is No Drug Shortage Of Our Type 2 Diabetes Drug Ozempic In The U.S. Market; On Compounded Versions Of Co's Drug Semaglutide In The U.S. Says "Focused On Securing Patients Have Access To High Quality Products"
诺和诺德首席执行官在谈到礼来公司在中国的糖尿病药物批准时说：“这是又一个有两个关键竞争者竞争的市场”；“尽我们所能供应”，我们的2型糖尿病药物Ozempic在美国市场不存在药物短缺问题；关于该公司在美国的复方药物Semaglutide表示 “专注于确保患者获得高质量产品”
- Reuters
-路透社
译文内容由第三方软件翻译。
以上内容仅用作资讯或教育之目的，不构成与富途相关的任何投资建议。富途竭力但不能保证上述全部内容的真实性、准确性和原创性。